Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction

Area of Science:

• Endocrinology
• Cell Biology
• Pharmacology

Background:

• Diabetes mellitus is a major global health concern.
• Glucosamine (GlcN) is used in diabetes management but can induce islet beta cell toxicity.
• Understanding GlcN-induced beta cell damage is crucial for therapeutic strategies.

Purpose of the Study:

• To investigate the protective effects of rosiglitazone (RSG) against glucosamine (GlcN)-induced apoptosis and dysfunction in islet beta cells.
• To elucidate the molecular mechanisms underlying RSG's protective action.

Main Methods:

• Utilized the HIT-T15 islet beta cell line.
• Administered GlcN to induce apoptosis and dysfunction.
• Assessed cell viability, apoptosis markers (Bcl-2, Bcl-xL, Bax, Bid, caspase-3), ATP production, and insulin secretion.
• Evaluated the effects of co-treatment with RSG and GlcN.

Main Results:

• GlcN induced HIT-T15 cell death through apoptosis, altering Bcl-2 family protein expression and increasing caspase-3 activity.
• GlcN treatment reduced ATP production and insulin secretion in a dose-dependent manner.
• Concurrent administration of RSG with GlcN significantly abrogated these GlcN-induced pathogenic changes.

Conclusions:

• Rosiglitazone (RSG) effectively inhibits glucosamine (GlcN)-induced apoptosis and dysfunction in islet beta cells.
• RSG may prevent GlcN-related complications in diabetes treatment by protecting beta cell function.
• This finding supports the potential therapeutic benefit of combining RSG with GlcN in managing diabetes.